Drug intelligence / Profile preview

Dulodent

Development stage: Unknown
Lead developer: Ardent Life Sciences
Modality: Small Molecules
Administration: Oral

Overview

Dulodent is a branded formulation of duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), marketed by Ardent Life Sciences. It is an oral small molecule primarily indicated for the treatment of major depressive disorder and generalized anxiety disorder. Duloxetine works by binding to and inhibiting the serotonin transporter (SERT) and the norepinephrine transporter (NET) in the central nervous system, thereby increasing the synaptic concentrations of these neurotransmitters. This dual action helps to alleviate symptoms of depression and anxiety. Dulodent is available in 20 mg and 30 mg tablet strengths for oral administration.

Brand names: Dulodent
Other names: duloxetine

Targets

SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on Dulodent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dulodent.

Explore the full profile